Certara/$CERT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Certara
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Ticker
$CERT
Sector
Primary listing
Industry
Health Care Technology
Headquarters
Employees
1,517
ISIN
US15687V1098
Website
Certara Metrics
BasicAdvanced
$1.8B
-
-$0.02
1.44
-
Price and volume
Market cap
$1.8B
Beta
1.44
52-week high
$16.93
52-week low
$8.64
Average daily volume
1.9M
Financial strength
Current ratio
2.777
Quick ratio
2.644
Long term debt to equity
27.819
Total debt to equity
28.514
Interest coverage (TTM)
1.17%
Profitability
EBITDA (TTM)
94.198
Gross margin (TTM)
60.26%
Net profit margin (TTM)
-0.67%
Operating margin (TTM)
7.24%
Effective tax rate (TTM)
63.58%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
0.97%
Return on equity (TTM)
-0.25%
Valuation
Price to revenue (TTM)
4.54
Price to book
1.66
Price to tangible book (TTM)
-11.57
Price to free cash flow (TTM)
25.48
Free cash flow yield (TTM)
3.92%
Free cash flow per share (TTM)
43.72%
Growth
Revenue change (TTM)
9.37%
Earnings per share change (TTM)
-94.88%
3-year revenue growth (CAGR)
9.44%
3-year earnings per share growth (CAGR)
-39.09%
What the Analysts think about Certara
Analyst ratings (Buy, Hold, Sell) for Certara stock.
Bulls say / Bears say
Certara's software revenue grew by 26% year-over-year in Q4 2024, indicating strong demand for its biosimulation products. (certara.com)
The acquisition of Chemaxon in October 2024 is expected to enhance Certara's biosimulation capabilities, potentially leading to increased market share. (certara.com)
Certara's adjusted EBITDA increased by 13% in Q4 2024, reflecting improved operational efficiency and profitability. (certara.com)
Certara's services revenue growth was only 7% in Q4 2024, indicating potential challenges in expanding this segment. (certara.com)
The net income of $6.6 million in Q4 2024, while positive, may not meet investor expectations for a company in a growth phase. (certara.com)
Certara's stock price has declined by approximately 33% from its 52-week high of $16.93, suggesting potential investor concerns. (cnbc.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Certara Financial Performance
Revenues and expenses
Certara Earnings Performance
Company profitability
Certara News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Certara stock?
Certara (CERT) has a market cap of $1.8B as of July 15, 2025.
What is the P/E ratio for Certara stock?
The price to earnings (P/E) ratio for Certara (CERT) stock is 0 as of July 15, 2025.
Does Certara stock pay dividends?
No, Certara (CERT) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Certara dividend payment date?
Certara (CERT) stock does not pay dividends to its shareholders.
What is the beta indicator for Certara?
Certara (CERT) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.